Increased GLP-1 adherence may reduce medical costs for a growing number of chronic conditions, but savings don’t offset the high price of the medications.

In a pilot of obesity care, Connecticut saved as much as 3% on medication spending, based on rejecting claims and switching members to lower net cost therapies.

The emergence of cost-plus reimbursement models in the pharmacy channel presents a promising alternative to better align reimbursement with acquisition costs.

We examine the impact of anti-obesity medication coverage in the Medicaid and commercial markets, as drugs such as Wegovy and Zepbound take off.

We examine various strategies related to GLP-1 medications such as Wegovy when used for weight loss to help payers understand the landscape, develop a coverage strategy, and minimize waste.

Drug manufacturers should take the time now to understand how the Inflation Reduction Act will affect Medicare and carefully plan.

We discuss three primary targets to reduce prescription drug costs in the U.S., with potentially substantial changes in pricing for Medicare Parts B and D.

This report estimates the distribution of Myasthenia Gravis patients among Medicare Fee for Service, Medicare Advantage, Commercial, and Medicaid payer channels.